🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Neurotrophic Keratopathy

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis NCT06999733Phase 1, Phase 29 sites📍 Irvine📍 Pasadena📍 Carmel Krystal Biotech, Inc. · Tests: KB801, Placebo Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease NCT06964269Phase 41 site📍 Nashville Toyos Clinic · Tests: Acthar Gel 80 UNT/ML Injectable Solution A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis NCT06975748Phase 21 site📍 Jinan Staidson (Beijing) Biopharmaceuticals Co., Ltd · Tests: STSP-0902 ophthalmic solution, STSP-0902 ophthalmic solution, STSP-0902 Placebo Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study NCT07566975n/a1 site📍 Houston Neuro-Ophthalmology of Texas · Tests: Cyclosporine ophthalmic solution 0.1% Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease NCT06919081Phase 21 site📍 Chicago University of Illinois at Chicago · Tests: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients NCT04700657n/a1 site📍 Indianapolis Indiana University · Tests: corneal sensation test Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 NCT05555589Phase 336 sites📍 Laguna Hills📍 Loma Linda📍 Colorado Springs ReGenTree, LLC · Tests: RGN-259, Placebo A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis NCT07568730Phase 26 sites📍 Tampa📍 Carmel📍 Russells Mills TearSolutions, Inc. · Tests: Lacripep, Vehicle Ophthalmic Solution Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy NCT04604834NA1 site📍 Monterrey Universidad Autonoma de Nuevo Leon · Tests: PFAT first, APRP first Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis NCT05927428Phase 21 site📍 Leland BRIM Biotechnology Inc. · Tests: BRM424 Ophthalmic Solution - Dose1, BRM424 Ophthalmic Solution - Dose2 An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED NCT07519902Phase 377 sites📍 Huntington Beach📍 Laguna Hills📍 Loma Linda Dompé Farmaceutici S.p.A · Tests: Cenegermin, Vehicle Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency NCT07502378Phase 41 site📍 Tampa University of South Florida · Tests: Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternativ…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy